People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

Adding time-restricted eating to usual care didn't offer extra benefits in reducing visceral fat but lowered subcutaneous fat ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

Health care, ride sharing, and the emerging world of YouTube entertainers are among industries leading investors have picked ...

The medicines may not only suppress appetite but also help curb alcoholism and other addictions. Read more at straitstimes.com.

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...